MedInCell Stock: Surge Driven by FDA's Acceptance of Olanzapine Filing

FDA Accepts MedInCell's Injectable Olanzapine for Review

MedInCell's stock rebounded after the release on Friday, February 20, of a statement confirming that the U.S. health agency has accepted the marketing authorization application for a monthly subcutaneous injectable formulation of olanzapine, intended for the treatment of schizophrenia in adults. This product, developed jointly with Teva Pharmaceuticals, is based on the French biotech's proprietary extended-release technology. The FDA's acceptance of this dossier marks a key milestone in the regulatory process and opens up prospects for commercialization in the world's leading drug market. Regarding the financial calendar, the company's upcoming milestones include the publication of the annual results for the fiscal year 2025-2026, scheduled for June 16, 2026, followed by the general meeting planned for September 10. These events will provide insights into the operational trajectory and revenues from ongoing partnerships.

Stock Performance and Technical Analysis

Despite today's rise, MedInCell's stock price is still below its 50-day moving average at 25.49 euros, a level that acts as an intermediate resistance. A sustained crossing of this threshold would be a short-term bullish reversal signal. However, the stock remains well above its 200-day moving average (22.62 euros), indicating a positive long-term trend. Over the past week, the stock has declined by 2.08% and shows a decrease of 13.31% over three months, correcting after a surge of more than 80% over a year. The most relevant technical support is around 22.56 euros, close to the lower Bollinger band. The monthly volatility remains contained at 21.16% with a beta of 0.61, reflecting moderate sensitivity to general market movements. The RSI, at 62, signals a stock in a neutral to slightly dynamic zone, without excessive buying or selling at this stage.